Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on disease-modifying treatments for neurodegenerative diseases, has successfully raised A$20.0 million through a strategic placement to international and Australian professional investors.

Alterity Therapeutics Limited (ASX: ATH; NASDAQ: ATHE) has announced highly promising topline results from its open-label Phase 2 clinical trial (ATH434-202) evaluating ATH434 in patients with advanced Multiple System Atrophy (MSA). The findings reinforce the company’s position as a front-runner in developing disease-modifying therapies for neurodegenerative diseases.